Cartesian Therapeutics share price logo

Cartesian Therapeutics

NASDAQ: RNAC

$6.49

-0.26

(-3.85%)

as on

Cartesian Therapeutics Stock Performance

as on October 31, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $6.46
    $6.75
    downward going graph

    0.46%

    Downside

    4.01%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.60
    $11.00
    downward going graph

    13.71%

    Downside

    69.49%

    Upside

    downward going graph

Cartesian Therapeutics share price movements today

Previous Close
$6.75
Open
$6.60
Volume
142.0K
Market Cap
$202.4M
Day's Low - High
$6.46 - $6.75
52 Week Low - High
$5.60 - $11.00

Cartesian Therapeutics Historical Returns

1 Month Return
-6.38 %
3 Month Return
-12.68 %
1 Year Return
-16.77 %
3 Year Return
0 %
5 Year Return
0 %

Cartesian Therapeutics Stock Fundamentals & Key Indicators

Check Cartesian Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$202.4M

EPS (TTM)

-5.93

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.08%

PE Ratio (TTM)

-1.13

Industry PE ratio

-3.27

PEG Ratio

0.01

EBITDA

-157.6M

Revenue (TTM)

1.5M

Profit Margin

-766.42%

Return On Equity TTM

141.41%

Cartesian Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cartesian Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Cartesian Therapeutics image
Cartesian Therapeutics
StrongBuy$202.4MNA-1.13-766.42%0.00%
Moderna image
Moderna
Neutral$88.5B-36.40%-27.78-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$141.7B208.09%32.2786.04%0.00%
Regeneron image
Regeneron
Buy$95.5B45.26%19.7685.77%0.40%

Stock Returns calculator for Cartesian Therapeutics Stock including INR - Dollar returns

The Cartesian Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Cartesian Therapeutics investment value today

Current value as on today

₹85,641

Returns

-₹14,359

(-14.36%)

Returns from Cartesian Therapeutics Stock

-₹19,975 (-19.98%)

Dollar Impact

₹5,616 (+5.62%)

Analyst Recommendation on Cartesian Therapeutics Stock

Based on 6 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 6 analysts, 100% of analysts recommend a 'BUY' rating for Cartesian Therapeutics. Average target price of $33.67

Cartesian Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Cartesian Therapeutics.

What analysts predicted

80.72%UPSIDE

Target Price

$33.67

Current Price

$6.49

Analyzed by

6 Analysts

High

$44

Target

$33.67

Low

$16

Cartesian Therapeutics target price $33.67, a slight upside of 80.72% compared to current price of $6.49. According to 6 analysts rating.

Indian Investors' Interest in Cartesian Therapeutics Stock

Search interest for Cartesian Therapeutics Stock has increased by 11% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:11% versus previous 30 day period

Cartesian Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
5
33
0
0
1
0
0
0
0
-
Gross Profit
5
33
0
0
1
0
-12
0
0
-
Operating Income
-13
13
-17
-26
-21
-21
-21
-21
-26
-29
EBITDA
-56
14
-23
-9
-16
16
-35
-101
-38
17
Interest Expense
-
-
-
-
-
-
-
-
-
0
Depreciation
0
0
0
0
1
0
0
0
0
0
Income Before Tax
-56
13
-24
-9
-17
15
-35
-101
-39
15
Income Tax Expense
-
-
-
0
-
-
-
-9
-
-
Net Income
-56
13
-24
-10
-17
15
-35
-92
-39
13
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
-2731.19%
100.00%
100.00%
0.00%

Cartesian Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
6
16
85
110
26
38
2
Gross Profit
0
0
6
16
85
108
26
38
2
Operating Income
-63
-65
-52
-56
-4
14
-86
-43
-86
EBITDA
-63
-62
-51
-66
-5
39
-235
-75
-136
Interest Expense
1
1
1
1
2
3
2
-
-
Depreciation
0
0
2
0
1
1
0
1
2
Income Before Tax
-65
-65
-55
-68
-9
34
-238
-77
-139
Income Tax Expense
-
-
-
-
15
0
-19
0
-9
Net Income
-65
-65
-55
-68
-25
35
-219
-77
-130
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
98.16%
100.00%
100.00%
100.00%

Cartesian Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-56
13
-24
-10
-17
15
-35
-92
-39
15
Operating Cash Flow
-15
-14
13
-7
-23
-17
-15
-17
-22
-20
Investing Cash Flow
0
-1
-6
0
-1
-2
-1
0
0
0
Financing Cash Flow
43
0
124
0
-8
0
0
0
15
34
Change in Cash
26
-15
131
-6
-32
-20
-16
-18
-6
13

Cartesian Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-65
-65
-55
-68
-25
35
-219
-77
-130
Operating Cash Flow
-52
-59
-51
34
-60
-31
-51
-23
-73
Investing Cash Flow
-2
25
0
0
-17
-15
34
-8
-5
Financing Cash Flow
66
0
105
14
52
39
-13
168
-8
Change in Cash
11
-33
52
48
-24
-7
-29
135
-87

Global Institutional Holdings in Cartesian Therapeutics

Check out the Institutions with significant holdings in Cartesian Therapeutics.

Funds
Holdings
Vanguard
2.10%
VANGUARD INDEX FUNDS
1.80%
TIAA-CREF Funds
1.71%
iShares
1.59%
Fidelity Select Portfolios
1.21%
See all

Cartesian Therapeutics News & Key Events

  • img

    Today's Timeline - 29 September

    Tue, 06:30 PM

    -

    Cartesian Therapeutics announces positive retreatment data for Descartes-08 in generalized myasthenia gravis patients.

Insights on Cartesian Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, RNAC stock has moved up by 472.0%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -92.57M → 13.72M (in $), with an average increase of 260.9% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, RNAC has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 720.2% return, outperforming this stock by 737.6%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 947.0K → 78.0K (in $), with an average decrease of 91.8% per quarter

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
OrganisationCartesian Therapeutics
Headquarters7495 New Horizon Way, Frederick, MD, 21703, US
IndustryBiotechnology
CEOCarsten Brunn

Key Management of Cartesian Therapeutics

Name

Title

Dr. Carsten Brunn Ph.D.

President, CEO & Chairman of the Board

Mr. Blaine T. Davis

Chief Financial Officer

Dr. Emily English Ph.D.

Chief Operating Officer

Ms. June Seymour

Chief Accounting Officer

Mr. Matthew Bartholomae J.D.

General Counsel & Secretary

Dr. Peter G. Traber M.D.

Head of R&D

FAQs

What is Cartesian Therapeutics share price today?

Cartesian Therapeutics share price today is $6.49 as on at the close of the market. Cartesian Therapeutics share today touched a day high of $6.75 and a low of $6.46.

What is the 52 week high and 52 week low for Cartesian Therapeutics share?

Cartesian Therapeutics share touched a 52 week high of $11.00 on and a 52 week low of $5.60 on . Cartesian Therapeutics stock price today i.e. is closed at $6.49,which is 41.00% down from its 52 week high and 15.89% up from its 52 week low.

What is Cartesian Therapeutics's market capitalisation today?

Cartesian Therapeutics market capitalisation is $0.00T as on .

How to invest in Cartesian Therapeutics Stock (RNAC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cartesian Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Cartesian Therapeutics Stock (RNAC) from India?

Indian investors can start investing in Cartesian Therapeutics (RNAC) shares with as little as ₹94.94999694824219 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.50 in Cartesian Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Cartesian Therapeutics share’s latest price of $6.49 as on October 31, 2026 at 8:45 am IST, you will get 1.5408 shares of Cartesian Therapeutics. Learn more about fractional shares .